RecruitingNot ApplicableNCT05384535

Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort


Sponsor

Northwell Health

Enrollment

100 participants

Start Date

Aug 15, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols.


Eligibility

Sex: MALEMin Age: 40 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether a prostate MRI scan can serve as an early screening tool to detect prostate cancer in men who are at higher-than-average risk but have a PSA level that falls in a gray zone — low enough that a biopsy is not usually recommended, but not zero. The aim is to catch cancer earlier in high-risk men without over-testing everyone. **You may be eligible if...** - Your PSA (prostate-specific antigen) blood test result is between 1.0 and 2.5 ng/mL - You are at higher risk for prostate cancer because you are Black, have a father or brother with prostate cancer, or carry a relevant genetic mutation **You may NOT be eligible if...** - Your prostate feels abnormal on physical exam (nodules or firmness) - You have had a prior prostate biopsy or prostate surgery - You are taking finasteride or dutasteride (medications for enlarged prostate) - You are unable to have an MRI scan (e.g., due to a pacemaker or claustrophobia) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTBi-parametric MRI

When used for the evaluation of prostate cancer, MRI typically involves multiple sequences and typically includes typical T1 and T2 phases with the addition of diffusion weighted imaging and dynamic contrast enhanced imaging. In this study, we have decided to omit dynamic contrast enhanced imaging due to its decreased diagnostic yield relative to T2 and DWI and associated increased risk of contrast agents, this is a common approach for prostate cancer screening and is referred to as a bi-parametric MRI


Locations(1)

Cynthia Knauer

Lake Success, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05384535


Related Trials